This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).
Introduction
Over recent years, facilitated by substantial advances in high-throughput analyses, multigene expression profiling has gained rapid development and become powerful tools for predicting the risk of relapse and mortality in patients with breast cancer.
The 21-gene recurrence score (RS) assay (Oncotype Dx, Genomic Health, Redwood City, CA) was calculated based on the results of a reverse transcriptase-polymerase chain reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissues [1] .
Previous studies have validated the ability of 21-gene assay to provide additional prognostic information beyond classical clinicopathological features in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative and node-negative invasive breast cancer treated with adjuvant tamoxifen or anastrozole alone [1, 2] . Additionally, 21-gene assay was validated to be capable of predicting benefit from adjuvant chemotherapy in node-negative and node-positive patients according to the analyses of the NSABP B-20 and SWOG-8814 trials [3, 4] . As a result of its excellent prognostic and predictive ability, 21-gene RS has been widely used by clinicians to help predict outcomes and make therapeutic decisions.
Mucinous breast cancer (MC) is a rare subtype of invasive breast cancer, with an incidence of 1%-6% in all primary breast cancer [5] [6] [7] [8] [9] [10] . Prior series indicated that the majority of MC were ERpositive, HER2-negative tumors without node metastasis [11] [12] [13] [14] , which matches the main criteria of 21-gene genomic test. However, the retrospective studies aimed at validating the prognostic value of RS did not distinguish among histological subtypes and the study cohorts were mainly compromised by infiltrating ductal carcinoma (IDC) [1, 3] . Given the relatively low incidence of MC, no study to date has explicated the prognostic significance of RS in MC.
Therefore, the objective of the current study was to evaluate the distribution pattern and prognostic value of RS in Chinese patients with MC compared to IDC. CANCER RESEARCH AND TREATMENT (CRT) 4 Korean Cancer Association This article is protected by copyright. All rights reserved.
Material and Methods

Study population and follow-up
Patients who were diagnosed with MC or IDC from January 2010 to January 2017 at Shanghai Jiao Tong University Affiliated Ruijin Hospital were retrospectively reviewed. The detailed inclusion criteria are as follows: (1) Disease-free survival (DFS) was defined as time from diagnosis to the earliest of disease recurrence including local/regional recurrence and distant metastasis in any site, second primary cancer or death of any cause. Overall survival (OS) was defined as time from diagnosis to death as a result of any cause. The last follow-up was conducted in March, 2018.
The current study has been approved by the Ethical Committees of Shanghai Ruijin Hospital. The results of this study do not affect the treatment decision of any patient included.
Sample preparation and RS calculation
The methods of sample preparation and RS calculation were similar with that previously Korean Cancer Association This article is protected by copyright. All rights reserved.
described [15, 16] . Briefly, hematoxylin and eosin-stained slides were reviewed by pathologists to make sure that the paraffin section used for 21-gene RS analysis contained sufficient tumor tissue. After RNA extraction and DNase I treatment, the RT-PCR reactions in 96 well plates were performed using Applied Biosystems (Foster City, CA) 7500 Real-Time PCR System.
Expression of 16 cancer-related genes was measured in triplicate and normalized relative to a set of five reference genes. The recurrence score, scaled from 0 to 100, was then calculated for each patient using the algorithm previously described in detail [1] . Patients were classified by the pre-specified cutoff points into low-risk (RS < 18), intermediate-risk (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and high-risk (RS > 30) groups.
Pathological assessment
The immunohistochemistry (IHC) assessment of biomarkers, including ER, PR, Ki-67 and Cerb-B 2, were conducted according to previously described protocols [17, 18] . 
Statistical analysis
The Pearson chi-square or Fisher exact test when necessary was performed to compare the distribution of clinicopathological characteristics in MC cohort versus IDC cohort and to assess the distribution of RS in patients with different clinicopathological characteristics. Multivariable logistic regression model was used to determine independent factors related to RS groups. Kaplan-Meier analyses were conducted to estimate the rate, and log-rank tests were performed to compare the survival curves. Multivariate Cox proportional hazards models were used to identify the independent prognostic factor for DFS and OS. All Statistical analyses were conducted with the statistical package STATA ver. 14.0 for Windows 10 (College Station, TX).
A p-value of less than 0.05 (two-sided) was considered to indicate a significant result.
Ethical statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the independent Ethical Committee/Institutional Review Board of Ruijin Hospital (14411950200) and with the 1964 Helsinki declaration and its later amendments 
Results
Clinicopathological features
The MC cohort included 128 patients, with 85 patients aged 50 and above (66.4%), while the IDC cohort included 707 patients, with 358 patients aged 50 and above (50.6%). Patients with MC were significantly older than patients with IDC (p=0.001). The baseline clinicopathological features of both cohorts were outlined in Table 1 .
Compared with IDC, patients with MC had less T1 tumors (MC vs. IDC, 54.7% vs. 69.9%; p < 0.001) and less lymph node involvement at diagnosis (MC vs. IDC, 6.2% vs. 13.2%; p < 0.028). In MC cohort, the mean and median Ki-67 index were 11.9% and 10%, while in IDC cohort, the mean and median Ki-67 index were 19.3% and 15%. The percentage of PR-positive tumors were similar between patients with MC and IDC (85.2% vs. 84.7%, p=0.900). With respect to the molecular subtype, there was no significant difference between the two cohorts (p=0.648), with 39.8% of luminal A-like tumors in MC cohort and 42% of luminal B-like tumors in IDC cohort.
In our series, the percentage of patients underwent breast-conserving surgery (BCS) and received radiation was similar in MC cohort and IDC cohort. However, chemotherapy was significantly less common in patients with MC (13.3%) than in patients with IDC (53.9%, p < 0.001). All patients received appropriate endocrine treatment.
Distribution of RS
With regard to RS category, the proportions of patients with low-, intermediate-and high-Korean Cancer Association
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Discussion
The current study evaluated the distribution pattern and prognostic significance of 21 and Ki-67 index were identified as independent predictors for RS in our previously study in 980 Chinese estrogen receptor-positive, HER2-negative breast cancer patients [15] .
Multivariate analyses in our current study showed that molecular subtype defined by Ki-67 and PR level was an independent predictor for RS in both MC and IDC cohorts. Luminal B-like tumors were more likely to have high-risk RSs. These facts indicated that routine clinical and pathologic parameters might be of help in predicting RS. risk groups were not statistically significant. Subgroup analyses conducted in patients without chemotherapy also confirmed this finding.
The possible reason for the negative results may lie in the favorable clinicopathological features and good prognosis in MC cohort. Previous study conducted in 11,400 patients with MC indicated that patients with pure MC had better outcomes than IDC patients [22] , with 10, 15 and 20 year survival rates were 89%, 85%, and 81%, respectively, compared to 82% (5 year), 72% (10 year), 66% (15 year), and 62% (20 year) for IDC. Another possible reason may be that the follow-up was not long enough and the sample size was small to observe the differences in survival.
According to our analyses, the percentage of patients of receiving chemotherapy was higher in the high-risk RS group compared with low-and intermediate-RS group, but the survival outcomes were not significantly different between patients with or without chemotherapy in each RS group (P>0.05). The potential benefit of chemotherapy in MC cohort may need longer follow-up and further investigation.
Pathological tumor size remained the significant predictor for DFS according to univariate analyses and was marginally significantly associated with DFS according to multivariate analyses which was possibly caused by the relatively short follow-up and limited number of events, indicating that traditional TNM (tumor size, nodal status, metastasis) classification system remained fundamental for tumor staging and prognosis prediction in patients with MC. Traditional clinicopathological factors that described tumor burden were of great value in predicting outcomes and making therapeutic decisions in MC, which were dominated by ERpositive, HER2-negative tumors. Based on the current study, RS didn't possess a distinct advantage over tumor burden in MC cohort.
In conclusion, patients with MC tend to have low-and intermediate-risk RS. Molecular Korean Cancer Association
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